VKH
SRPT icon

Virtu KCG Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Virtu KCG Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,361
Closed -$307K – 3461
2017
Q1 		$307K Buy
+10,361
New +$321K 0.01% 1930
2016
Q1 		– Sell
-24,592
Closed -$949K – 3591
2015
Q4 		$949K Buy
24,592
+10,012
+69% +$325K 0.02% 911
2015
Q3 		$468K Buy
14,580
+7,812
+115% +$265K 0.01% 1598
2015
Q2 		$206K Buy
+6,768
New +$138K ﹤0.01% 2553
2014
Q3 		– Sell
-9,748
Closed -$290K – 4042
2014
Q2 		$290K Buy
+9,748
New +$308K ﹤0.01% 2614
2014
Q1 		– Sell
-17,163
Closed -$349K – 4040
2013
Q4 		$349K Buy
17,163
+12,253
+250% +$364K ﹤0.01% 2387
2013
Q3 		$232K Buy
+4,910
New +$189K ﹤0.01% 2938

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtu KCG Holdings's SRPT Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 10,361 shares — an estimated $307K sold.

Virtu KCG Holdings first reported a position in SRPT in Q3 2013 and held it in 7 quarters. The position peaked at $949K in Q4 2015. 189 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 10,361 Sarepta Therapeutics shares in Q2 2017, an estimated $307K.
  • Virtu KCG Holdings first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 7 quarters.
  • Virtu KCG Holdings's Sarepta Therapeutics position peaked at $949K in Q4 2015.
  • 189 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.